Transaktionen anzeigen
Healthcare

Igyxos S.A. has completed a Series A fundraising

Igyxos S.A. has completed a US$8.4 million fundraising as part of a Series A funding led by Bpifrance through its FABS Fund, with participation from the Go Capital Amorçage II and Loire Valley Invest Funds and by the Emergence Innovation II. This will allow the founder Marie Christine Maurel and Professor René Frydman, joined by Pierre-Henry Longeray (ex Merck Serono) as CEO, to pursue the proof of concept in human clinical practice.

Based in Nouzilly, France, biotechnology startup Igyxos is developing a new treatment for female and male infertility that works by shifting hormonal imbalances with a new method using monoclonal antibodies.

Oaklins’ team in France advised Igyxos on a "dual-track" project that allowed them to validate with the industry both scientific and therapeutic interest of its drug candidate based on the use of monoclonal antibodies to improve the treatment of female and male infertility.

Art der transaktion
Finanzierung, Fremdkapitalberatung & ECM
BETEILIGTE PARTEIEN
“This fundraising of US$8.4 million associated with the arrival of Pierre-Henry Longeray as CEO, and the support and expertise of Professor René Frydman, who has been with us from the beginning, gives us real hope to see the treatment developed by Igyxos successfully reach the market. We thank Oaklins’ team in France for their efficient and strong support.”

Marie-Christine Maurel

CSO and Founder, Igyxos, S.A.

Sprechen Sie mit dem Deal-Team

 Jean-Paul  Ortelli

Jean-Paul Ortelli

Senior Advisor

Paris, Frankreich
Oaklins France
 Leïla  Djebli

Leïla Djebli

Associate Director

Paris, Frankreich
Oaklins France

Transaktionen

Global Media Santé has been acquired by SFP Expansion
Private Equity | Healthcare | TMT

Global Media Santé has been acquired by SFP Expansion

Global Media Santé’s CEO, Alain Trébucq, and Apax Partners have sold the company to SFP Expansion Group.

Mehr erfahren
Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate
Healthcare

Synairgen has successfully raised US$114 million to support phase III trial of COVID candidate

Synairgen plc has completed its oversubscribed equity fundraising to raise US$114 million to fund a phase III trial for 900 patients for the effects of its SNG001 drug on patients with COVID-19. In addition, the raise will be used to scale up manufacturing and device activities.

Mehr erfahren
Westminster Homecare has been acquired by Care at Home
Healthcare

Westminster Homecare has been acquired by Care at Home

The private shareholders of Westminster Homecare Ltd. have sold the company to Care at Home Services (South East) Ltd.

Mehr erfahren